Christopher DeSouza
Concepts (406)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cell-Derived Microparticles | 17 | 2025 | 71 | 10.150 |
Why?
| | Endothelium, Vascular | 47 | 2025 | 935 | 9.520 |
Why?
| | Vasodilation | 31 | 2025 | 509 | 6.600 |
Why?
| | Endothelial Cells | 19 | 2025 | 790 | 5.950 |
Why?
| | Endothelin-1 | 18 | 2025 | 177 | 5.670 |
Why?
| | Vasoconstriction | 14 | 2025 | 219 | 3.910 |
Why?
| | Fibrinolysis | 16 | 2023 | 147 | 3.270 |
Why?
| | Human Umbilical Vein Endothelial Cells | 8 | 2025 | 107 | 2.990 |
Why?
| | Nitric Oxide | 15 | 2025 | 892 | 2.930 |
Why?
| | Tissue Plasminogen Activator | 18 | 2024 | 229 | 2.870 |
Why?
| | Vasodilator Agents | 23 | 2025 | 329 | 2.850 |
Why?
| | Forearm | 19 | 2025 | 138 | 2.780 |
Why?
| | Hypertension | 14 | 2023 | 1249 | 2.680 |
Why?
| | Sleep Deprivation | 6 | 2021 | 181 | 2.560 |
Why?
| | Spinal Cord Injuries | 5 | 2025 | 231 | 2.560 |
Why?
| | Aging | 40 | 2025 | 1857 | 2.550 |
Why?
| | Obesity | 20 | 2025 | 2994 | 2.470 |
Why?
| | Nitric Oxide Synthase Type III | 9 | 2025 | 200 | 2.240 |
Why?
| | MicroRNAs | 7 | 2025 | 676 | 2.120 |
Why?
| | Overweight | 9 | 2018 | 573 | 2.080 |
Why?
| | Acetylcholine | 18 | 2025 | 203 | 1.970 |
Why?
| | Exercise | 34 | 2024 | 2086 | 1.770 |
Why?
| | Middle Aged | 113 | 2025 | 33782 | 1.700 |
Why?
| | Prehypertension | 5 | 2015 | 27 | 1.670 |
Why?
| | Regional Blood Flow | 24 | 2025 | 496 | 1.660 |
Why?
| | Apoptosis | 16 | 2025 | 2551 | 1.640 |
Why?
| | Vasomotor System | 2 | 2025 | 47 | 1.570 |
Why?
| | Blood Pressure | 20 | 2021 | 1737 | 1.530 |
Why?
| | Cardiovascular Diseases | 11 | 2021 | 2058 | 1.530 |
Why?
| | HIV Envelope Protein gp120 | 3 | 2019 | 61 | 1.490 |
Why?
| | Polycythemia | 2 | 2021 | 24 | 1.390 |
Why?
| | Sleep | 5 | 2021 | 800 | 1.370 |
Why?
| | Stem Cells | 8 | 2012 | 599 | 1.360 |
Why?
| | Postmenopause | 18 | 2023 | 376 | 1.230 |
Why?
| | NG-Nitroarginine Methyl Ester | 3 | 2024 | 49 | 1.210 |
Why?
| | Nitroprusside | 16 | 2021 | 71 | 1.200 |
Why?
| | Male | 94 | 2025 | 68250 | 1.190 |
Why?
| | tat Gene Products, Human Immunodeficiency Virus | 2 | 2019 | 24 | 1.170 |
Why?
| | Enzyme Inhibitors | 6 | 2024 | 850 | 1.170 |
Why?
| | Circulating MicroRNA | 2 | 2019 | 24 | 1.150 |
Why?
| | C-Reactive Protein | 7 | 2015 | 411 | 1.130 |
Why?
| | Metabolic Syndrome | 4 | 2016 | 346 | 1.120 |
Why?
| | Humans | 140 | 2025 | 138972 | 1.070 |
Why?
| | Nebivolol | 2 | 2017 | 10 | 1.050 |
Why?
| | Atherosclerosis | 2 | 2023 | 401 | 1.050 |
Why?
| | Cell Movement | 8 | 2014 | 969 | 1.040 |
Why?
| | Platelet Endothelial Cell Adhesion Molecule-1 | 3 | 2011 | 50 | 1.000 |
Why?
| | Peptides, Cyclic | 7 | 2013 | 265 | 0.990 |
Why?
| | Caspase 3 | 5 | 2017 | 251 | 0.980 |
Why?
| | Adult | 70 | 2025 | 38393 | 0.950 |
Why?
| | Erythritol | 1 | 2025 | 2 | 0.940 |
Why?
| | Inflammation Mediators | 5 | 2024 | 513 | 0.940 |
Why?
| | Sweetening Agents | 1 | 2025 | 55 | 0.900 |
Why?
| | Microvessels | 2 | 2025 | 86 | 0.900 |
Why?
| | Vasoconstrictor Agents | 6 | 2023 | 133 | 0.880 |
Why?
| | Female | 84 | 2025 | 74016 | 0.880 |
Why?
| | Cells, Cultured | 10 | 2025 | 4182 | 0.870 |
Why?
| | Aged | 66 | 2025 | 24172 | 0.860 |
Why?
| | Work-Life Balance | 1 | 2024 | 22 | 0.860 |
Why?
| | Fibrin Fibrinogen Degradation Products | 2 | 2023 | 91 | 0.830 |
Why?
| | Extracellular Vesicles | 1 | 2025 | 148 | 0.800 |
Why?
| | Physical Endurance | 16 | 2024 | 273 | 0.790 |
Why?
| | Goals | 1 | 2024 | 177 | 0.780 |
Why?
| | Dietary Fats | 2 | 2015 | 301 | 0.770 |
Why?
| | Oxidative Stress | 8 | 2025 | 1318 | 0.760 |
Why?
| | Blood Coagulation | 2 | 2021 | 262 | 0.730 |
Why?
| | Estrogen Replacement Therapy | 9 | 2003 | 148 | 0.690 |
Why?
| | Vascular Diseases | 1 | 2023 | 240 | 0.690 |
Why?
| | Biomarkers | 13 | 2025 | 4095 | 0.680 |
Why?
| | Altitude | 3 | 2021 | 467 | 0.660 |
Why?
| | Physical Fitness | 12 | 2005 | 207 | 0.630 |
Why?
| | Case-Control Studies | 11 | 2021 | 3574 | 0.620 |
Why?
| | Acclimatization | 1 | 2021 | 168 | 0.610 |
Why?
| | Hemodynamics | 8 | 2021 | 1093 | 0.610 |
Why?
| | Cross-Sectional Studies | 23 | 2023 | 5530 | 0.600 |
Why?
| | Ascorbic Acid | 3 | 2021 | 179 | 0.580 |
Why?
| | T-Lymphocyte Subsets | 2 | 2011 | 416 | 0.580 |
Why?
| | Endothelium | 3 | 2020 | 126 | 0.580 |
Why?
| | Dose-Response Relationship, Drug | 9 | 2017 | 2047 | 0.570 |
Why?
| | Telomere | 3 | 2010 | 274 | 0.570 |
Why?
| | Metoprolol | 1 | 2017 | 25 | 0.550 |
Why?
| | Hematopoietic Stem Cells | 2 | 2011 | 409 | 0.540 |
Why?
| | HIV | 1 | 2019 | 246 | 0.540 |
Why?
| | Plethysmography | 5 | 2017 | 109 | 0.540 |
Why?
| | Blood Glucose | 7 | 2019 | 2241 | 0.530 |
Why?
| | Hyperglycemia | 2 | 2018 | 357 | 0.530 |
Why?
| | Bradykinin | 8 | 2015 | 46 | 0.520 |
Why?
| | Receptor, Endothelin A | 2 | 2014 | 63 | 0.510 |
Why?
| | Stress, Physiological | 2 | 2017 | 450 | 0.500 |
Why?
| | Plasminogen Activator Inhibitor 1 | 7 | 2023 | 86 | 0.500 |
Why?
| | HIV Infections | 4 | 2019 | 2945 | 0.500 |
Why?
| | Cytokines | 4 | 2020 | 2083 | 0.500 |
Why?
| | Cellular Senescence | 1 | 2018 | 190 | 0.490 |
Why?
| | Body Mass Index | 15 | 2017 | 2390 | 0.480 |
Why?
| | Young Adult | 13 | 2025 | 13371 | 0.480 |
Why?
| | Nitric Oxide Synthase | 4 | 2017 | 241 | 0.470 |
Why?
| | Interleukin-6 | 6 | 2025 | 785 | 0.460 |
Why?
| | Blood Pressure Determination | 2 | 2016 | 143 | 0.460 |
Why?
| | Gender Identity | 2 | 2006 | 126 | 0.450 |
Why?
| | Reactive Oxygen Species | 3 | 2025 | 627 | 0.450 |
Why?
| | Diet, High-Fat | 2 | 2018 | 247 | 0.440 |
Why?
| | Endothelial Progenitor Cells | 1 | 2014 | 20 | 0.420 |
Why?
| | Interleukin-8 | 3 | 2025 | 271 | 0.420 |
Why?
| | Brain | 2 | 2025 | 2791 | 0.410 |
Why?
| | Blood Platelets | 1 | 2017 | 427 | 0.410 |
Why?
| | Analysis of Variance | 7 | 2016 | 1317 | 0.410 |
Why?
| | Glucose | 2 | 2017 | 1031 | 0.400 |
Why?
| | Adiposity | 3 | 2016 | 522 | 0.400 |
Why?
| | Infusions, Intra-Arterial | 5 | 2013 | 61 | 0.390 |
Why?
| | Colony-Forming Units Assay | 6 | 2014 | 96 | 0.390 |
Why?
| | Transcription Factor RelA | 2 | 2024 | 85 | 0.390 |
Why?
| | Blood Vessels | 1 | 2014 | 180 | 0.380 |
Why?
| | Arteries | 7 | 2018 | 263 | 0.380 |
Why?
| | Endothelin A Receptor Antagonists | 4 | 2014 | 26 | 0.380 |
Why?
| | Alkalosis, Respiratory | 2 | 2023 | 2 | 0.380 |
Why?
| | Inflammation | 5 | 2025 | 2853 | 0.370 |
Why?
| | Coronary Disease | 3 | 2007 | 372 | 0.370 |
Why?
| | Oxygen Consumption | 12 | 2024 | 710 | 0.370 |
Why?
| | Body Composition | 14 | 2009 | 695 | 0.370 |
Why?
| | Anti-HIV Agents | 1 | 2019 | 836 | 0.360 |
Why?
| | Glucose Intolerance | 1 | 2013 | 146 | 0.360 |
Why?
| | T-Lymphocytes | 2 | 2010 | 1985 | 0.360 |
Why?
| | Muscle, Smooth, Vascular | 5 | 2010 | 450 | 0.350 |
Why?
| | NF-kappa B | 3 | 2025 | 678 | 0.350 |
Why?
| | Time Factors | 10 | 2021 | 6869 | 0.350 |
Why?
| | Abdominal Fat | 1 | 2011 | 41 | 0.350 |
Why?
| | Age Factors | 9 | 2025 | 3276 | 0.350 |
Why?
| | Fatty Acids | 1 | 2014 | 445 | 0.340 |
Why?
| | Antigens, CD34 | 1 | 2011 | 89 | 0.340 |
Why?
| | Muscle Tonus | 2 | 2010 | 22 | 0.340 |
Why?
| | HIV Protease Inhibitors | 1 | 2011 | 68 | 0.330 |
Why?
| | Risk Factors | 14 | 2018 | 10385 | 0.330 |
Why?
| | Dyslipidemias | 1 | 2012 | 169 | 0.330 |
Why?
| | Chemotaxis | 1 | 2010 | 133 | 0.320 |
Why?
| | HIV-1 | 2 | 2019 | 886 | 0.320 |
Why?
| | Heart Failure | 1 | 2023 | 2065 | 0.320 |
Why?
| | Cholesterol, LDL | 1 | 2012 | 359 | 0.320 |
Why?
| | Health | 1 | 2010 | 84 | 0.320 |
Why?
| | Postprandial Period | 3 | 2019 | 110 | 0.310 |
Why?
| | Disease | 1 | 2010 | 102 | 0.310 |
Why?
| | Sleep Wake Disorders | 1 | 2013 | 301 | 0.300 |
Why?
| | Feeding Behavior | 1 | 2015 | 685 | 0.300 |
Why?
| | Flow Cytometry | 4 | 2019 | 1192 | 0.300 |
Why?
| | Vascular Endothelial Growth Factor A | 4 | 2014 | 550 | 0.290 |
Why?
| | Muscarinic Agonists | 1 | 2008 | 15 | 0.280 |
Why?
| | Phosphorylation | 2 | 2024 | 1767 | 0.280 |
Why?
| | Fasting | 4 | 2019 | 283 | 0.270 |
Why?
| | Reference Values | 7 | 2016 | 801 | 0.270 |
Why?
| | omega-N-Methylarginine | 3 | 2015 | 31 | 0.260 |
Why?
| | Endothelin Receptor Antagonists | 4 | 2011 | 62 | 0.260 |
Why?
| | Exercise Therapy | 4 | 2017 | 440 | 0.260 |
Why?
| | Adult Stem Cells | 1 | 2006 | 40 | 0.250 |
Why?
| | Dinucleotide Repeats | 1 | 2005 | 5 | 0.240 |
Why?
| | Epigenesis, Genetic | 1 | 2010 | 644 | 0.230 |
Why?
| | Double-Blind Method | 5 | 2021 | 1949 | 0.230 |
Why?
| | Hyperthermia, Induced | 2 | 2023 | 120 | 0.220 |
Why?
| | Myocardial Ischemia | 1 | 2006 | 278 | 0.220 |
Why?
| | Walking | 5 | 2018 | 541 | 0.220 |
Why?
| | Premenopause | 5 | 2002 | 132 | 0.220 |
Why?
| | Adipose Tissue | 6 | 2005 | 645 | 0.210 |
Why?
| | Physiology | 1 | 2024 | 14 | 0.210 |
Why?
| | Blood Flow Velocity | 3 | 2012 | 411 | 0.210 |
Why?
| | Estrogen Receptor alpha | 1 | 2005 | 145 | 0.210 |
Why?
| | Signal Transduction | 5 | 2025 | 5092 | 0.210 |
Why?
| | Endothelin B Receptor Antagonists | 2 | 2014 | 11 | 0.210 |
Why?
| | Quadriplegia | 1 | 2023 | 13 | 0.210 |
Why?
| | Carotid Arteries | 5 | 2003 | 195 | 0.210 |
Why?
| | Antihypertensive Agents | 4 | 2013 | 503 | 0.210 |
Why?
| | Hypertrophy | 2 | 2023 | 136 | 0.200 |
Why?
| | von Willebrand Factor | 1 | 2023 | 81 | 0.200 |
Why?
| | Actinin | 1 | 2023 | 13 | 0.200 |
Why?
| | Thrombophilia | 1 | 2023 | 86 | 0.200 |
Why?
| | Troponin T | 1 | 2023 | 65 | 0.190 |
Why?
| | Running | 5 | 2000 | 230 | 0.190 |
Why?
| | Contraceptives, Oral | 1 | 2002 | 43 | 0.190 |
Why?
| | Receptor, Endothelin B | 2 | 2014 | 46 | 0.190 |
Why?
| | Vaping | 1 | 2023 | 61 | 0.190 |
Why?
| | Career Choice | 1 | 2024 | 230 | 0.190 |
Why?
| | Electronic Nicotine Delivery Systems | 1 | 2023 | 103 | 0.180 |
Why?
| | Breathing Exercises | 1 | 2021 | 20 | 0.180 |
Why?
| | Respiratory Muscles | 1 | 2021 | 34 | 0.180 |
Why?
| | Inhalation | 1 | 2021 | 29 | 0.180 |
Why?
| | Sex Characteristics | 4 | 2017 | 766 | 0.180 |
Why?
| | Colorado | 6 | 2024 | 4543 | 0.180 |
Why?
| | Diet, Sodium-Restricted | 1 | 2001 | 38 | 0.170 |
Why?
| | South America | 1 | 2021 | 59 | 0.170 |
Why?
| | Estradiol | 1 | 2025 | 525 | 0.170 |
Why?
| | Peru | 1 | 2021 | 61 | 0.170 |
Why?
| | Diet, Carbohydrate-Restricted | 2 | 2018 | 37 | 0.170 |
Why?
| | Lymphocyte Count | 2 | 2011 | 166 | 0.170 |
Why?
| | Endothelins | 1 | 2021 | 63 | 0.170 |
Why?
| | Healthy Lifestyle | 1 | 2021 | 34 | 0.170 |
Why?
| | Drug Administration Schedule | 2 | 2016 | 769 | 0.170 |
Why?
| | Fibrosis | 1 | 2023 | 539 | 0.160 |
Why?
| | Cytochromes c | 2 | 2010 | 60 | 0.160 |
Why?
| | Tumor Necrosis Factor-alpha | 3 | 2015 | 1244 | 0.160 |
Why?
| | Transforming Growth Factor beta | 1 | 2023 | 488 | 0.160 |
Why?
| | Diabetes Mellitus, Type 2 | 3 | 2019 | 2516 | 0.160 |
Why?
| | Chemokine CXCL12 | 2 | 2010 | 83 | 0.160 |
Why?
| | Fibrinogen | 2 | 1998 | 173 | 0.160 |
Why?
| | Piperidines | 2 | 2013 | 216 | 0.160 |
Why?
| | Oligopeptides | 2 | 2013 | 266 | 0.160 |
Why?
| | Physical Exertion | 2 | 1998 | 209 | 0.150 |
Why?
| | Fever | 2 | 2020 | 305 | 0.150 |
Why?
| | Insulin Glargine | 1 | 2019 | 84 | 0.150 |
Why?
| | Cell Proliferation | 1 | 2006 | 2480 | 0.150 |
Why?
| | Risk Reduction Behavior | 1 | 2021 | 216 | 0.150 |
Why?
| | Chronic Disease | 1 | 2025 | 1804 | 0.150 |
Why?
| | E-Selectin | 1 | 2018 | 56 | 0.150 |
Why?
| | Hemoglobins | 1 | 2021 | 357 | 0.150 |
Why?
| | HIV Antibodies | 1 | 2019 | 61 | 0.150 |
Why?
| | Infusions, Intravenous | 2 | 2011 | 411 | 0.150 |
Why?
| | Myocytes, Cardiac | 1 | 2023 | 513 | 0.140 |
Why?
| | Telomerase | 2 | 2011 | 247 | 0.140 |
Why?
| | Phenotype | 2 | 2021 | 3143 | 0.140 |
Why?
| | Brachial Artery | 3 | 2017 | 202 | 0.140 |
Why?
| | Heat-Shock Response | 1 | 2018 | 75 | 0.140 |
Why?
| | Adrenergic beta-1 Receptor Antagonists | 1 | 2017 | 8 | 0.140 |
Why?
| | Follow-Up Studies | 3 | 2017 | 5152 | 0.140 |
Why?
| | Antioxidants | 1 | 2021 | 593 | 0.140 |
Why?
| | Vascular Cell Adhesion Molecule-1 | 1 | 1997 | 42 | 0.140 |
Why?
| | Dietary Carbohydrates | 1 | 2018 | 154 | 0.140 |
Why?
| | Myocardial Infarction | 1 | 2005 | 1063 | 0.140 |
Why?
| | Biomedical Research | 1 | 2024 | 695 | 0.140 |
Why?
| | Treatment Outcome | 5 | 2021 | 10921 | 0.130 |
Why?
| | Pilot Projects | 1 | 2023 | 1765 | 0.130 |
Why?
| | Heart | 1 | 2021 | 612 | 0.130 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 1997 | 142 | 0.130 |
Why?
| | Lipids | 3 | 2009 | 675 | 0.130 |
Why?
| | Prognosis | 3 | 2018 | 3995 | 0.120 |
Why?
| | Infusions, Intraosseous | 1 | 2016 | 18 | 0.120 |
Why?
| | Anthropometry | 2 | 2011 | 213 | 0.120 |
Why?
| | Triglycerides | 3 | 2005 | 513 | 0.120 |
Why?
| | Enzyme Activation | 1 | 2017 | 819 | 0.120 |
Why?
| | Baroreflex | 3 | 2001 | 56 | 0.120 |
Why?
| | Substance P | 2 | 2008 | 37 | 0.120 |
Why?
| | Insulin | 2 | 2005 | 2447 | 0.120 |
Why?
| | Isoproterenol | 2 | 2008 | 101 | 0.110 |
Why?
| | Down-Regulation | 1 | 2017 | 636 | 0.110 |
Why?
| | Blood Circulation | 1 | 2015 | 44 | 0.110 |
Why?
| | Insulin Resistance | 2 | 2003 | 1222 | 0.110 |
Why?
| | Interleukin-18 | 2 | 2006 | 236 | 0.110 |
Why?
| | Hot Temperature | 1 | 2017 | 392 | 0.110 |
Why?
| | Cross-Over Studies | 4 | 2017 | 555 | 0.110 |
Why?
| | Peptides | 1 | 2019 | 980 | 0.100 |
Why?
| | Regression Analysis | 5 | 2011 | 1021 | 0.100 |
Why?
| | Physical Education and Training | 2 | 2024 | 73 | 0.100 |
Why?
| | Interleukin-10 | 1 | 2015 | 304 | 0.100 |
Why?
| | Hydrocortisone | 1 | 2015 | 313 | 0.100 |
Why?
| | Cholinergic Agonists | 1 | 2011 | 7 | 0.090 |
Why?
| | Injections, Intravenous | 1 | 2012 | 202 | 0.090 |
Why?
| | Blood Volume | 4 | 1999 | 65 | 0.090 |
Why?
| | Obesity, Abdominal | 1 | 2011 | 48 | 0.090 |
Why?
| | Waist Circumference | 1 | 2011 | 140 | 0.090 |
Why?
| | Plaque, Atherosclerotic | 1 | 2011 | 58 | 0.080 |
Why?
| | Femoral Artery | 2 | 2002 | 182 | 0.080 |
Why?
| | Circadian Rhythm | 1 | 2015 | 489 | 0.080 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2011 | 193 | 0.080 |
Why?
| | Vital Capacity | 2 | 2002 | 312 | 0.080 |
Why?
| | Hypoglycemic Agents | 1 | 2019 | 1343 | 0.080 |
Why?
| | Prevalence | 3 | 2014 | 2745 | 0.080 |
Why?
| | Plant Lectins | 1 | 2010 | 8 | 0.080 |
Why?
| | Staurosporine | 1 | 2010 | 20 | 0.080 |
Why?
| | Cholesterol | 2 | 2005 | 403 | 0.080 |
Why?
| | Estrogens | 2 | 2003 | 370 | 0.080 |
Why?
| | Granulocyte Colony-Stimulating Factor | 1 | 2010 | 88 | 0.080 |
Why?
| | Bone Diseases, Metabolic | 1 | 2010 | 64 | 0.080 |
Why?
| | Immunoenzyme Techniques | 1 | 2009 | 209 | 0.080 |
Why?
| | Cerebrovascular Circulation | 2 | 2023 | 269 | 0.080 |
Why?
| | Aged, 80 and over | 6 | 2003 | 7685 | 0.080 |
Why?
| | CD3 Complex | 1 | 2009 | 104 | 0.080 |
Why?
| | Cell Separation | 1 | 2010 | 317 | 0.080 |
Why?
| | Leg | 2 | 2001 | 233 | 0.080 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2011 | 368 | 0.080 |
Why?
| | Life Style | 5 | 2003 | 484 | 0.080 |
Why?
| | Norepinephrine | 1 | 2009 | 192 | 0.070 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2011 | 442 | 0.070 |
Why?
| | Up-Regulation | 1 | 2012 | 852 | 0.070 |
Why?
| | Adolescent | 6 | 2025 | 21581 | 0.070 |
Why?
| | Endothelin-Converting Enzymes | 1 | 2008 | 9 | 0.070 |
Why?
| | Aspartic Acid Endopeptidases | 1 | 2008 | 31 | 0.070 |
Why?
| | Metalloendopeptidases | 1 | 2008 | 59 | 0.070 |
Why?
| | Methacholine Chloride | 1 | 2008 | 49 | 0.070 |
Why?
| | Cell Count | 1 | 2008 | 325 | 0.070 |
Why?
| | Calcium Channel Blockers | 1 | 2008 | 172 | 0.070 |
Why?
| | Hemiplegia | 2 | 1997 | 21 | 0.070 |
Why?
| | Arm | 1 | 2007 | 108 | 0.060 |
Why?
| | Coronary Circulation | 1 | 2007 | 136 | 0.060 |
Why?
| | Risk Assessment | 1 | 2016 | 3466 | 0.060 |
Why?
| | Probability | 1 | 2007 | 308 | 0.060 |
Why?
| | Lipoproteins, LDL | 1 | 2006 | 113 | 0.060 |
Why?
| | Microscopy, Phase-Contrast | 1 | 2005 | 17 | 0.060 |
Why?
| | Thymidine | 1 | 2005 | 60 | 0.060 |
Why?
| | Muscle, Skeletal | 3 | 2002 | 1734 | 0.060 |
Why?
| | DNA Methylation | 1 | 2010 | 636 | 0.060 |
Why?
| | Weight Loss | 1 | 2010 | 783 | 0.050 |
Why?
| | Anaerobic Threshold | 2 | 2005 | 28 | 0.050 |
Why?
| | France | 1 | 2024 | 37 | 0.050 |
Why?
| | Bone Marrow Cells | 1 | 2005 | 326 | 0.050 |
Why?
| | Hypocapnia | 1 | 2023 | 8 | 0.050 |
Why?
| | Hyperventilation | 1 | 2023 | 14 | 0.050 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2008 | 448 | 0.050 |
Why?
| | Thrombosis | 1 | 2007 | 374 | 0.050 |
Why?
| | History, 21st Century | 1 | 2024 | 214 | 0.050 |
Why?
| | Compliance | 4 | 2008 | 50 | 0.050 |
Why?
| | Adenine | 1 | 2005 | 301 | 0.050 |
Why?
| | Fenofibrate | 1 | 2003 | 27 | 0.050 |
Why?
| | Body Weight | 2 | 2005 | 996 | 0.050 |
Why?
| | History, 20th Century | 1 | 2024 | 324 | 0.050 |
Why?
| | Muscarinic Antagonists | 1 | 2003 | 30 | 0.050 |
Why?
| | Heart Rate | 4 | 2001 | 801 | 0.050 |
Why?
| | Oxidation-Reduction | 1 | 2006 | 1076 | 0.050 |
Why?
| | Bicycling | 1 | 2024 | 114 | 0.050 |
Why?
| | Hypertriglyceridemia | 1 | 2003 | 39 | 0.050 |
Why?
| | Polymorphism, Genetic | 1 | 2005 | 624 | 0.050 |
Why?
| | Sensitivity and Specificity | 1 | 2007 | 1939 | 0.050 |
Why?
| | Exercise Test | 3 | 2005 | 621 | 0.050 |
Why?
| | Adrenergic beta-Agonists | 1 | 2002 | 97 | 0.050 |
Why?
| | Carotid Artery Diseases | 1 | 2002 | 61 | 0.050 |
Why?
| | Carbon Dioxide | 1 | 2023 | 241 | 0.050 |
Why?
| | Progesterone | 1 | 2003 | 258 | 0.040 |
Why?
| | Tunica Intima | 4 | 2002 | 76 | 0.040 |
Why?
| | Universities | 1 | 2024 | 434 | 0.040 |
Why?
| | Systole | 1 | 2001 | 174 | 0.040 |
Why?
| | Heart Conduction System | 1 | 2001 | 89 | 0.040 |
Why?
| | Cardiovascular Physiological Phenomena | 1 | 2000 | 44 | 0.040 |
Why?
| | Ultrasonography | 5 | 2002 | 748 | 0.040 |
Why?
| | Mexican Americans | 1 | 2001 | 114 | 0.040 |
Why?
| | Knee | 1 | 2000 | 69 | 0.040 |
Why?
| | Predictive Value of Tests | 1 | 2005 | 2030 | 0.040 |
Why?
| | Hemorheology | 1 | 2018 | 22 | 0.040 |
Why?
| | Body Constitution | 1 | 1998 | 54 | 0.040 |
Why?
| | Energy Intake | 2 | 1998 | 506 | 0.040 |
Why?
| | Social Class | 1 | 2001 | 278 | 0.040 |
Why?
| | Drug Combinations | 1 | 2019 | 346 | 0.040 |
Why?
| | Oxygen | 1 | 2024 | 977 | 0.040 |
Why?
| | Diet, Fat-Restricted | 1 | 2018 | 78 | 0.040 |
Why?
| | Hemostasis | 1 | 1998 | 86 | 0.030 |
Why?
| | Plasminogen Activators | 1 | 1997 | 7 | 0.030 |
Why?
| | Cervical Vertebrae | 1 | 2018 | 143 | 0.030 |
Why?
| | Vascular Resistance | 1 | 1998 | 364 | 0.030 |
Why?
| | Gait | 2 | 1997 | 303 | 0.030 |
Why?
| | United States | 1 | 2014 | 15074 | 0.030 |
Why?
| | Cohort Studies | 1 | 2007 | 5744 | 0.030 |
Why?
| | Movement Disorders | 1 | 1997 | 64 | 0.030 |
Why?
| | Cerebrovascular Disorders | 1 | 1997 | 96 | 0.030 |
Why?
| | Chromium | 1 | 1996 | 16 | 0.030 |
Why?
| | Weight Lifting | 1 | 1996 | 32 | 0.030 |
Why?
| | Leukocytes, Mononuclear | 1 | 2018 | 571 | 0.030 |
Why?
| | Gene Expression Regulation | 1 | 2025 | 2591 | 0.030 |
Why?
| | Neoplasms | 1 | 2010 | 2687 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2017 | 1235 | 0.030 |
Why?
| | Hypoxia | 1 | 2021 | 1148 | 0.030 |
Why?
| | Antigens | 1 | 1996 | 356 | 0.030 |
Why?
| | Swimming | 3 | 1999 | 50 | 0.030 |
Why?
| | Menopause | 1 | 1997 | 326 | 0.030 |
Why?
| | Melatonin | 1 | 2015 | 154 | 0.030 |
Why?
| | Defibrillators, Implantable | 1 | 1997 | 305 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2019 | 1522 | 0.030 |
Why?
| | Brain Ischemia | 1 | 1997 | 343 | 0.030 |
Why?
| | Tunica Media | 2 | 2001 | 35 | 0.020 |
Why?
| | Sex Factors | 1 | 1996 | 2050 | 0.020 |
Why?
| | Animals | 3 | 2024 | 37243 | 0.020 |
Why?
| | Cardiac Output | 2 | 1998 | 177 | 0.020 |
Why?
| | Prospective Studies | 4 | 2001 | 7661 | 0.020 |
Why?
| | Bone Density | 1 | 2010 | 489 | 0.020 |
Why?
| | Stroke Volume | 2 | 1998 | 584 | 0.010 |
Why?
| | Hemostatics | 1 | 2005 | 56 | 0.010 |
Why?
| | Hypolipidemic Agents | 1 | 2003 | 90 | 0.010 |
Why?
| | Fatty Acids, Nonesterified | 1 | 2003 | 158 | 0.010 |
Why?
| | Lipoproteins | 1 | 2003 | 160 | 0.010 |
Why?
| | Absorptiometry, Photon | 1 | 2002 | 263 | 0.010 |
Why?
| | Blood Viscosity | 1 | 2001 | 18 | 0.010 |
Why?
| | Thoracic Arteries | 1 | 2000 | 4 | 0.010 |
Why?
| | Habits | 1 | 2001 | 51 | 0.010 |
Why?
| | Thigh | 1 | 2000 | 48 | 0.010 |
Why?
| | Thinness | 1 | 2000 | 95 | 0.010 |
Why?
| | Mexico | 1 | 2001 | 232 | 0.010 |
Why?
| | Elasticity | 1 | 2000 | 194 | 0.010 |
Why?
| | Erythrocyte Volume | 1 | 1999 | 6 | 0.010 |
Why?
| | Plasma Volume | 1 | 1999 | 20 | 0.010 |
Why?
| | Femur | 1 | 2001 | 260 | 0.010 |
Why?
| | Stress, Mechanical | 1 | 2001 | 487 | 0.010 |
Why?
| | Supine Position | 1 | 1998 | 37 | 0.010 |
Why?
| | Posture | 1 | 1999 | 192 | 0.010 |
Why?
| | Signal Processing, Computer-Assisted | 1 | 1998 | 147 | 0.010 |
Why?
| | Hematocrit | 1 | 1997 | 103 | 0.010 |
Why?
| | Rest | 1 | 1997 | 123 | 0.010 |
Why?
| | Electric Conductivity | 1 | 1997 | 86 | 0.010 |
Why?
| | Socioeconomic Factors | 1 | 2001 | 1312 | 0.010 |
Why?
| | Ventricular Fibrillation | 1 | 1997 | 60 | 0.010 |
Why?
| | Electrodes, Implanted | 1 | 1997 | 112 | 0.010 |
Why?
| | Hyperlipidemias | 1 | 1997 | 124 | 0.010 |
Why?
| | Diabetes Complications | 1 | 1997 | 224 | 0.010 |
Why?
| | Equipment Design | 1 | 1997 | 518 | 0.010 |
Why?
| | Electrocardiography | 1 | 1998 | 610 | 0.010 |
Why?
| | Tachycardia, Ventricular | 1 | 1997 | 172 | 0.010 |
Why?
| | Multivariate Analysis | 1 | 1998 | 1497 | 0.010 |
Why?
| | Kinetics | 1 | 1997 | 1649 | 0.010 |
Why?
| | Stroke | 1 | 2002 | 1140 | 0.010 |
Why?
| | Heart Arrest | 1 | 1997 | 383 | 0.010 |
Why?
| | Survival Rate | 1 | 1997 | 1934 | 0.010 |
Why?
| | Length of Stay | 1 | 1997 | 1237 | 0.010 |
Why?
| | Energy Metabolism | 1 | 1997 | 927 | 0.010 |
Why?
| | Smoking | 1 | 1997 | 1610 | 0.000 |
Why?
| | Retrospective Studies | 1 | 2003 | 15901 | 0.000 |
Why?
|
|
DeSouza's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|